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ABSTRACT
Background: Intradialytic hypotension is a potential complication experienced by patients with
end-stage renal disease who receive hemodialysis. This complication occurs during the dialysis
treatment in 15-30% of all treatments. The multiple comorbidities that exist in hemodialysis
patients predispose them to recurrent intradialytic hypotension episodes. Recurrent intradialytic
hypotensive episodes can result in negative short-term and long-term clinical consequences.
Short-term consequences include complications such as ischemic events (e.g., heart attacks,
strokes), clotting of patient dialysis access, or heart rhythm abnormalities. Long-term
consequences include end-organ damage, increased cardiovascular morbidity, and a higher
mortality rate. Problem Statement: Available nursing interventions used to treat intradialytic
hypotension such as decreased dialysis fluid temperature, changes in the calcium and sodium
concentrations in the dialysis fluid and oral medication have limited success. Another existing
technological intervention called blood volume monitoring shows greater potential success but is
currently underutilized. Purpose: The purpose of this literature review is to synthesize current
literature on blood volume monitoring technology used to prevent intradialytic hypotension in
hemodialysis patients. Methods: A literature review was conducted analyzing pertinent research
articles published in the last ten years, in addition to seminal articles. Seventeen articles were
retrieved and analyzed that met criteria. Results: Fourteen of the seventeen research studies
reached a consensus on the successful use of blood volume monitoring to decrease intradialytic
hypotension and the related symptoms. Conclusion: Results of the literature review support the
use of blood volume monitoring technology as an effective nursing intervention to prevent
intradialytic hypotension in hemodialysis patients.
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INTRODUCTION
Intradialytic hypotension (IDH) is an incommodious and pernicious side effect seen in
many patients with end-stage renal disease (ESRD) who receive hemodialysis (HD). IDH can
result in serious complications, including ischemic events, vascular access thrombosis,
dysrhythmias, and mesenteric venous infarction (Kidney Dialysis Outcomes Quality Initiatives
Workgroup [KDOQI], 2005). Other long-term complications may include fluid volume overload
due to fluid resuscitation, left ventricular hypertrophy (LVH), and interdialytic hypertension
(KDOQI Workgroup, 2005). Nurses are at the forefront of dialysis care and are in a unique
position to recognize early signs of IDH and intervene.
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SIGNIFICANCE
IDH occurs in 15%-30% of HD treatments (Reilly, 2014). The incidence increases to
50% with predisposed ESRD individuals, with comorbidities like diabetes and cardiac anomalies
(Reilly, 2014).
Intradialytic systolic blood pressure (SBP) of <100 mm Hg, with a predialysis SBP of
≥160 mm Hg in patients who receive HD is associated with increased mortality (Reeves & Mc
Causland, 2018). Patients with intradialytic SBP of <90 mm Hg with a predialysis SBP of <160
mm Hg have the same increased risk of mortality (Reeves & Mc Causland, 2018). Van Buren
and Inrig (2017) noted that the risk of death is greater among patients with a decrease in SBP of
≥30 mm Hg from pre- to post-dialysis. Alternatively, Reeves and Causland (2018) found that
absolute blood pressure declines (30 mm Hg from pre-dialysis blood pressure) had no
association with mortality rates, suggesting that there is a threshold below which end-organ
hypoperfusion occurs. The higher the frequency of IDH occurrence, the greater the mortality rate
(Reeves & Mc Causland, 2018).
Transient oxygen deprivation to myocardial tissue from IDH causes prolonged left
ventricular (LV) systolic dysfunction, also called myocardial stunning (Ok, Levin, Asci, Chazot,
Tox, & Ozkahya, 2017). Although ischemic episodes of short duration may not cause cardiac
cell death, they may eventually lead to permanent damage to LV function (Ok et al., 2017).
During dialysis, patients without significant coronary artery disease (CAD) show LV wall
abnormalities and decreased blood flow to cardiac muscle tissue (Ok et al., 2017).
Dialysis-related LV systolic dysfunction is linked to decreased LV ejection fraction,
higher endotoxin level, and increased risk of mortality (Ok et al., 2017). According to Dasselaar
et al. (2009), non-diabetic patients who underwent dialysis with a minimal ultrafiltration (UF)
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had a decrease in myocardial blood volume within the first 30 minutes of treatment, without
substantial blood pressure or blood volume changes. IDH has been independently linked to
cardiac mortality, myocardial infarction, and hospitalization for heart failure and volume
overload (Reeves & Mc Causland, 2018).
Intradialytic blood pressure declines are associated with decreased blood flow to the
middle cerebral artery, leading to hypoperfusion of brain tissue (Reeves & Mc Causland, 2018).
Consequently, higher incidence of IDH is associated with a decrease in frontal brain area to
intracranial frontal space (Reeves & Mc Causland, 2018) and cognitive decline (Chou, KalantarZadeh & Mathew, 2017). MRI findings of patients with IDH include cerebral infarcts, atrophy,
and leukoaraiosis (caused by the deprivation of oxygen and is a risk factor for dementia and
strokes) (Chou, Kalantar-Zadeh, & Matthew, 2017).
Hemodynamic instability with IDH also causes the gut to displace endotoxins across the
intestinal lining causing bowel edema and hypoperfusion (Chou et al., 2017). Patients on HD
have high endotoxin levels that aid in creating pro-inflammatory processes that lead to
malnutrition, wasting, and poor cardiovascular outcomes (Chou et al., 2017). This increase in
endotoxin levels is due, in part, to poor mesenteric blood flow during dialysis (Chou et al.,
2017).
Patients with greater decline in SBP had two times the risk of developing thrombosis in
their vascular access (i.e., arteriovenous fistula, arteriovenous graft, or central venous catheter)
during follow-up (Reeves & Mc Causland, 2018). Patients with an IDH frequency of >29% had
twice the risk of developing thrombosis in their vascular access compared to patients without
IDH (Ok et al., 2017).
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PROBLEM STATEMENT
Although dialysis technology has improved in the past decade, the frequency of IDH
remains unchanged (Reilly, 2014). Many HD patients continue to experience IDH, despite the
use of current interventions, such as decreased dialysate temperature, sodium and calcium
modeling, and the use of midodrine (KDOQI Workgroup, 2005). IDH contributes to long-term
complications such as end-organ damage, increased cardiovascular morbidity, and a greater
mortality rate (Reilly, 2014). Given the substantial adverse complications associated with IDH
including increased morbidity and mortality, a currently existing, but underutilized, dialysis
technology intervention merits further consideration (Reilly, 2014). The use of blood volume
monitoring (BVM) is one such technological advancement that nurses can utilize to prevent IDH.
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PURPOSE
The purpose of this literature review is to synthesize the current literature on BVM with
biofeedback UF technology used to prevent IDH in HD patients.
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BACKGROUND
Intradialytic Hypotension
IDH is an intradialytic complication where blood pressure is markedly decreased in
response to fluid volume and urea removal. IDH is defined as a decrease in SBP ≥ 20 mm Hg or
a decrease in mean arterial pressure (MAP) of ≥ 10 mm Hg during a dialysis treatment (KDOQI
Workgroup, 2005). Symptoms accompanying IDH include nausea, vomiting, muscle cramps,
and dizziness (KDOQI Workgroup, 2005). Consequently, the treatment of IDH-related
symptoms, after they occur, may lead to suboptimal dialysis treatments and affect the Kt/V (the
laboratory value reflecting the toxin removal from the blood). The Kt/V value reflects the
effectiveness of dialysis treatment and indicates whether changes in dialysis prescription are
merited (KDOQI Workgroup, 2005). Established measures used to treat IDH when it occurs
currently include decreasing dialysate temperature, sodium and calcium modeling, and the use of
pharmacologic agents, such as midodrine (ProAmatine) (KDOQI Workgroup, 2005). There is no
established measure to prevent IDH in clinical practice.
Risk Factors for IDH
Non-modifiable risk factors for IDH include older age (>60 years of age) (KDOQI,
2005), female gender, Hispanic ethnicity, and increased number of years on dialysis (Chou et al.,
2017). Patients with the following comorbidities are predisposed to IDH: diabetes mellitus (DM),
CAD, systolic dysfunction, LVH, and increased cardiac enzymes (Chou et al., 2017). IDH risk
factors that can be modified with patient health behavior change include hyperphosphatemia,
antihypertensive medication usage, eating a meal before hemodialysis treatments, increased body
mass index, decreased albumin levels, and interdialytic fluid weight gain (Chou et al., 2017).
Dialysis prescription of low sodium dialysate (fluid used to clean blood during dialysis) (≤ 135
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mmol/L) is associated with increased frequency of IDH, while higher dialysate calcium is
associated with decreased rate of IDH (Chou et al., 2017).
Pathophysiology of IDH
To address how IDH occurs, the different factors that affect blood pressure must be
considered. Blood pressure is determined by blood volume, systemic vascular resistance, and
cardiac output (Santos, Peixoto, & Perazella, 2012). Hemodialysis may cause impairment in
more than one of these factors, affecting the body’s normal compensatory mechanism (Santos et
al., 2012).
High UF rates (the rate at which the blood is cleaned, and fluid is removed during
dialysis) is often higher than the patient’s plasma volume (Agarwal, 2012; Santos et al., 2012).
Elevated UF rates, combined with decreased extracellular osmolality, cause a drastic reduction in
plasma volume (Reeves et al., 2018; Santos et al., 2012). These combined processes lead to
reduced plasma refilling and hemodynamic instability (Reilly, 2014; Santos et al., 2012). The
effects are greater in patients with impaired vascular compliance and blood redistribution (Santos
et al., 2012).
Vasoconstriction of the splenic and cutaneous circulation occurs to compensate for lack
of plasma refilling, leading to decreased venous pooling (Reeves et al., 2018; Santos et al.,
2012). This mechanism redistributes blood to the central blood compartment to support adequate
cardiac filling and cardiac output (Chou et al.,2017; Santos et al., 2012). This compensatory
process of blood redistribution is impaired in ESRD patients due to their comorbidities (Reilly,
2014; Santos et al., 2012). Increased core temperatures during dialysis cause the blood to
redistribute from the central circulation to the skin (to reduce core temperature), further
decreasing central blood volume (Santos et al., 2012).
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Patients with DM, structural heart disease, and the elderly are afflicted with autonomic
dysfunction, decreased function of cardiopulmonary receptors, and diminished arterial
pressoreceptors (Reilly, 2014; Santos et al., 2012). Patients at greater risk of IDH were identified
as having impaired resting baroreflex sensitivity (Agarwal, 2012; Santos et al., 2012). The
uremic component of autonomic dysfunction is linked to the development of IDH (Agarwal,
2012; Santos et al., 2012). There is also an imbalance between vasoconstrictor (less endothelin1) and vasodilator (elevated nitric oxide) processes supporting vasodilation which predisposes
patients to IDH (Santos et al., 2012).
Some ESRD patients may have large amounts of adenosine production from oxygendeprived tissues during UF (Santos et al., 2012). Elevated adenosine is believed to decrease
blood pressure by reducing norepinephrine secretion and stimulating vasodilation and venous
blood pooling (Bradshaw, 2014; Santos et al., 2012). Vasopressin release in some IDH patients
is deficient and escalates hemodynamic instability (Santos et al., 2012).
Patients in HD have circulating endotoxemia (immune marker indicating low grade
inflammation), which is associated with increased relative IDH (Agarwal, 2012; Santos et al.,
2012). ESRD patients with any of the disorders (impaired resting baroreflex sensitivity,
increased adenosine production, or endotoxemia) cannot compensate by increasing vascular
resistance. Their inability to compensate breeds a perfect environment for IDH to occur (Chou et
al., 2017; Santos et al., 2012).
Another underlying structural cardiac abnormality that frequently results in IDH is LVH
(Chou et al., 2017; Santos et al., 2012). In patients with ESRD, LVH is caused by long-standing
hypertension, chronic volume overload, severe anemia, and arteriovenous shunts (Santos et al.,
2012). LVH is the most prevalent cardiac anomaly in ESRD patients (Santos et al., 2012).
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LVH is frequently associated with systolic or diastolic cardiac dysfunction, which may
increase the propensity of patients to develop IDH (Chou et al., 2017; Santos et al., 2012).
Cardiac output decreases when intravascular blood volume, central blood volume, and cardiac
preload are reduced. The diminished cardiac output, as seen with systolic and diastolic
dysfunction, can precipitate a drop in blood pressure and lead to IDH occurrence (Santos et al.,
2012).
Current IDH Interventions
There are four interventions currently in practice to treat IDH: decreasing dialysate
temperature, sodium modeling, calcium modeling, and pharmaceutical intervention. These
interventions will be described in greater detail.
Dialysis Interventions Used to Treat IDH When It Occurs.
Decreasing Dialysate Temperature.
During HD, it is common for the core body temperature to increase (due to heat load
from the dialysis machine or secondary to volume removal) (KDOQI Workgroup, 2005). Once
core temperatures reach a critical level (level at which the body’s homeostatic mechanism are
triggered), peripheral dilation occurs (Reilly, 2014), leading to an increased risk of IDH (KDOQI
Workgroup, 2005). Lower dialysate temperature (decreasing dialysate temperature lower than
the patient’s core temperature) compared with standard dialysate temperature (37° C) is thought
to reduce the frequency and intensity of symptomatic IDH (KDOQI Workgroup, 2005). Lower
dialysate temperature is related to a decline in LV regional wall abnormalities, improved
peripheral vasopressor reactions, and an increase in baroreceptor sensitivity (Reilly, 2014). The
patients may complain of feeling cold with this intervention (Reilly, 2014) and patients are at an
increased risk of diminished Kt/V (Larkin, Reviriego-Mendoza, Usvyat, Kotanko, & Maddux,
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2017). Many dialysis patients are already hypothermic, making them inadequate candidates for
this intervention (Reilly, 2014). This treatment modality is only useful on the short-term basis
(Larkin et al., 2017). Larkin et al. (2017) did a literature review on the effectiveness of
decreasing dialysate temperature and found that there is a lack of studies to suggest the
effectiveness of decreasing dialysate temperature for the long-term prevention of IDH.
Sodium Modeling.
Sodium modeling is an intervention in which the sodium dialysate concentration is higher
at the beginning of dialysis and decreases gradually towards the end of the dialysis treatment
(KDOQI Workgroup, 2005). Nurses preset the HD machine according to a physician’s or nurse
practitioner’s orders before the start of the HD treatment to carry out sodium modeling
automatically. Sodium profiling prevents IDH by increasing extracellular fluid sodium levels at
the time of peak UF, which helps shift water from the intracellular space to the extracellular
space and improves venous refill and prevents the Bezold-Jarisch reflex (a cardiovascular
mechanism activated in response to decreased oxygenation levels to myocardial tissue that leads
to vasodilation, bradycardia, and hypotension [Johnson, 2013, p. 215]) (KDOQI Workgroup,
2005).
Sodium profiling also ameliorates the urea equilibrium between the intracellular fluid and
extracellular fluid (KDOQI Workgroup, 2005). Using higher levels of dialysate sodium
concentrations during the start of dialysis necessitates lower than mean dialysate sodium
concentration towards the end of treatment (Reilly, 2014).
During the period when lower sodium concentration is implemented, the patients are at a
higher risk of IDH (Reilly, 2014). The ramification of sodium modeling is a positive sodium
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balance in the patient at the end of dialysis which often leads to elevated blood pressure,
increased thirst, and increased interdialytic weight gain (Chou et al., 2017).
Calcium Modeling.
Low calcium dialysate is associated with decreased LV contraction and hypotension
(KDOQI Workgroup, 2005). Associations between low calcium baths and low blood pressure
affect IDH-prone patients and non-IDH prone patients (KDOQI Workgroup, 2005). Increased
calcium concentrate in dialysate provides increased stroke volume, increased SBP, and elevated
serum calcium concentration (Reilly, 2014).
In a small subgroup of predisposed IDH individuals, Reilly (2014) found that changes in
MAP were modest and did not result in a significant decrease in IDH occurrence. Higher calcium
dialysates, for example a 3.5 mEq/L calcium bath, can cause hypercalcemia and significantly
increase the risk of decreased bone turnover (KDOQI Workgroup, 2005). Given the minimal
effects of calcium modeling on IDH and the increased risk of positive calcium balance, changing
calcium dialysate prescription is not commonly used (Reilly, 2014).
Pharmaceutical Intervention.
Midodrine (ProAmatine) is a selective alpha one agonist and has an off-label use for IDH
prevention (Chou et al., 2017). The use of Midodrine is associated with a decrease in the
severity of symptoms related to IDH (KDOQI Workgroup, 2005). It prevents IDH by preserving
the central blood volume and cardiac output with a marginal increase in peripheral vascular
resistance (KDOQI Workgroup, 2005). Dialysis patients self-administer this medication 30
minutes before the initiation of HD, as this medication is not available to nurses in outpatient
dialysis clinics (Chou et al., 2017). A second dose is administered halfway through the treatment,
if needed (Reilly, 2014). The peak action of the drug is one hour after administration, and it is
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dialyzed out of the body. Thus, the half-life of the medication on dialysis is three hours (Reilly,
2014). Some patients experience unpleasant side effects from midodrine such as pruritus, supine
hypertension, and goosebumps, which may discourage use of the medication (Chou et al., 2017).
The side effect of supine hypertension occurs in less than 10% of patients, but, warrants
cessation of the medication for patients who experience this side effect (KDOQI Workgroup,
2005).
Dialysis Technological Intervention Used to Prevent IDH.
Blood Volume Monitoring.
A technological device used to monitor blood volume is one in which the patient’s
relative blood volume (RBV) is recorded in real time throughout the HD treatment (Bradshaw,
2014; Micklos, 2013). These devices non-invasively monitor relative blood volume, hematocrit,
and oxygen saturation (Gul, 2016). Some newer dialysis machines come equipped with a blood
volume monitor, however, one can be added to the dialysis machine (e.g., Crit-line monitor)
(Micklos, 2013).
A Crit-line monitor measures RBV based on hematocrit (Micklos, 2013). It measures
hematocrit concentration using photo-optical technology, a sensor emitting a light beam through
the blood chamber, the red blood cells reflect the light, the dispersion of the light change due to
fluctuations in hematocrit concentrations, and these values are recorded (Micklos, 2013).
In machines equipped with a blood volume monitor, the RBV is tracked in response to
changes in hematocrit levels. Specific prompts advise the nurse when the UF rate is less than,
equal to, or greater than the plasma refill rate (Bradshaw, 2014). The fluid removal progress is
also displayed on the dialysis machine screen (Bradshaw, 2014). The RBV trends provide more
information on the patient’s hemodynamic stability rather than the absolute value at any point in
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time during the dialysis treatment (Bradshaw, 2014). The greater the slope of RBV, the greater
the fluid removal rate compared to the plasma refill rate, which does not allow for safer removal
of fluid volume and precipitates IDH (Bradshaw, 2014).
Over successive HD treatments, critical RBV (threshold in which the plasma refill rate is
greater than the fluid removal rate) levels are determined by the nephrology team for each patient
(Bradshaw, 2014). Once the machine is programmed by the dialysis nurse based on each
patient’s critical RBV, the biofeedback mechanism will inform staff when critical RBV is
achieved and will automatically adjust the UF rate accordingly, thus preventing IDH (Bradshaw,
2014).
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METHODS
A literature review was conducted analyzing the articles published in the last ten years, in
addition to seminal articles. CINAHL, Cochrane Central Register of Controlled Trials, Cochrane
Database of Systematic Reviews, Medline, and PsychINFO were utilized to identify journals
published in nursing. Search terms included: (a) dialysis, (b) intradialytic, (c) dialysis patients,
(d) ultrafiltration (and UF, modeling, profiling, monitoring, and biofeedback), (e) hypoten* (and
low blood pressure), and (f) blood volume. The population was limited to patients ≥18 years old.
The search was limited by those published in English. Duplicate articles were excluded.
Each article was evaluated individually to determine the relevancy of using BVM to
determine the UF rate by a title and abstract review. Hierarchy of evidence was considered to
assess the reliability and validity of each article. An evidence table was developed to organize
the journals and significant findings. A synthesis of the research is presented as a thesis.
By using the search criteria and limiters, a total of 85 journal articles were retrieved.
After the title review, 43 articles went under an abstract review, resulting in 12 articles that met
the inclusion and exclusion criteria. Five seminal articles were included, accruing a total of 17
articles analyzed in this literature review.
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FINDINGS
The literature review demonstrated a consensus that BVM biofeedback technology not
only decreased the frequency of IDH but also offered other benefits during treatment. The
analyzed studies included randomized control trials (7), nonrandomized control trials (1),
prospective studies (5), systematic review and metanalysis (1), pilot study (1), prospective audit
(1), and descriptive clinical evaluation (1). The findings are divided into two sections based on
the relevant themes found in the review: 1. IDH & intradialytic morbid events (IME) and 2.
adequacy & target weight.
Intradialytic Hypotension & Intradialytic Morbid Events
BVM technology demonstrated a reduction in IMEs, which are described as symptomatic
hypotensive episodes, muscle cramps, nausea, dizziness, headache vomiting, unconsciousness, or
other adverse symptoms requiring nursing intervention (Gabrielli et al., 2009).
Winkler et al. (2008) found similar results in a descriptive clinical evaluation of diabetic
patients with cardiac disease. BVM corrected cardiac function and reduced the pure water
overload triggered by diabetes and intermittent hyperglycemia (Winkler et al., 2008). The
improved refilling rates significantly increased ejection fraction and nearly normalized left
ventricular mass index (p < 0.05) (Winkler et al., 2008). Clinically, the use of BVM significantly
reduced IDH (p < 0.01) and muscle cramps (p < 0.01) (Winkler et al., 2008).
In a prospective study, McIntyre et al. (2003) showed that treatments using BVM had an
IME reduction of 1.5% during HD treatments. McIntyre et al. (2003) identified that BVM
technology reduced the incidence of symptomatic and asymptomatic IDH in the patient
population prone to IDH and those not prone to IDH (p < 0.001).
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In a randomized crossover study, Veljančic et al. (2011) further explained that although
not all patients benefit from BVM and blood temperature monitoring (BTM), both account for
more than 70% of patients experiencing fewer IMEs compared to standard hemodialysis (SHD)
(p = 0.024). Veljančic et al. (2011) observed that the combination of BVM and BTM contributed
to a 45% reduction in IMEs compared to non-isothermal HD. The results were partially
attributed to the blood volume control mechanism rather than the BTM (Veljančic et al., 2011).
Steurer et al. (1996) conducted a single sample nonrandomized trial to study five patients
for a total of 106 dialysis treatment sessions. The patient sample underwent a control session
with SHD alternating with an experimental session, in which BVM was the independent
variable. The authors found that blood pressure was not a predictor of intradialytic morbidity.
Other symptoms (i.e., muscle cramping, lightheadedness, and nausea) correlated with
hypovolemia, although intradialytic symptoms were not constantly reflected by blood pressure
changes (Steurer et al., 1996). The variability in intradialytic morbid events and hypotension was
due to other factors that affected blood volume shifts, including predialysis hydration status,
physical exertion, mental state, and neurohormonal compensatory mechanisms (Steurer et al.,
1996). Monitoring blood volume demonstrated that it was more beneficial than blood pressure
monitoring in preventing IDH related to hypovolemia (p = 0.02) (Steurer et al., 1996). Every
subject who experienced IDH and intradialytic symptoms did so at specific hematocrit thresholds
(Steurer et al., 1996). This hematocrit threshold was consistent for each patient in subsequent
treatments (Steurer et al., 1996). Sessions complicated by IMEs resulted from exceeding the
subject’s hematocrit threshold (Steurer et al., 1996).
Basile et al. (2001) conducted a prospective randomized crossover study utilizing
bicarbonate dialysis treatment in addition to BVM-guided UF. Their study revealed that BVM
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improved intra- and inter- dialytic symptoms, specifically symptomatic IDH related to
hypovolemia (p < 0.02). Basile et al. (2001), also analyzed the effectiveness and safety of longterm dialysate monitoring. Although Basile et al. (2001), did not measure the sodium mass
balance directly, there was sufficient evidence to suggest that that sodium balance was not
different between the gold standard bicarbonate treatment and the bicarbonate treatment with
BVM. Blood pressure, body weight, and serum sodium levels remained unchanged and were
identical in a follow up of two years (Basile et al., 2001).
Santoro et al. (2002) utilized a multicenter prospective randomized crossover study to
demonstrate that the decrease in IME was due to BVM allowance for greater equilibrium
throughout the dialysis treatment. This subjected the body to fewer extreme conditions, both in
refilling and pressure. The decreased exposure to extreme conditions led to saved energy and
contributed to a decrease in morbid symptoms (Santoro et al., 2002). Sessions complicated by
IDH was 33.5% in group A (alternating between standard HD followed by BVM treatment) and
23.5% in the group B (BVM treatments were initiated first followed by SHD) (p = 0.004)
(Santoro et al., 2002). Group A IDH rates decreased from 34% to 20% when transitioning from
SHD to BVM HD (Santoro et al., 2002). In group B, IDH rates went from 31% in the BVM
period to 30% in the SHD period (p > 0.05). In the second trial, the IDH rates increased from
28% in the BVM period to 39% in the conventional HD period (Santoro et al., 2002). Rates of
interdialytic symptoms were also significantly reduced (p < 0.001), and better post dialysis
tolerance was noted (p < 0.001) (Santoro et al., 2002). The patient population that received the
greatest benefit from the application of BVM were unstable cardiovascular patients – the more
critical the patient, the greater the benefits (Santoro et al., 2002). Patients with refilling problems
and those who have significant intradialytic hypovolemia reaped more benefits from the
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continuous use of BVM as compared to patients with good plasma refilling rates, but with
cardiomyopathies (Santoro et al., 2002).
In a randomized crossover study, Gabrielli et al. (2009), observed that treatments
utilizing BVM had a reduction of IME from 40% to 32% compared to SHD (p = 0.02). BVM
was effective in 46% of the sample (Gabrielli et al., 2009). The rate of symptomatic IDH and the
average number of episodes were dramatically reduced with the use of BVM (p = 0.04)
(Gabrielli et al., 2009). The need for intervention for IMEs and IDH were reduced, but did not
reach statistical significance (p > 0.05) (Gabrielli et al., 2009). The blood pressures and heart
rates from the beginning to the end of HD treatments were not significantly different between the
BVM group and the control group (p > 0.05) (Gabrielli et al., 2009).
Gil et al. (2014) conducted a prospective crossover study and found that IDH was
significantly reduced with the use of BVM (p < 0.001). Other observed benefits were a
significant reduction in time to recover from fatigue after dialysis (p = 0.048) and a greater
reduction in IDH related nursing interventions (p < 0.001) (Gil et al., 2014). The lower the rate
of IDH, the less the degree of patient fatigue after dialysis (p = 0.002) (Gil et al., 2014). These
results were seen among diabetic and non-diabetic patients (Gil et al., 2014). The number of
IMEs without IDH did not significantly differ between SHD and BVM sessions (p > 0.05) (Gil et
al., 2014).
Saxena et al. (2015) conducted a longitudinal pilot study and evaluated the use of BVM
with BTM compared to a control group not receiving BVM with BTM in a patient population
noncompliant with fluid restrictions. The researchers found dialysis treatments uneventful – no
incidence of IDH or IMEs. The patients remained stable throughout the dialysis treatment
(Saxena et al., 2015). The authors demonstrated that the use of BVM and BTM was highly
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accurate and delivered safe HD to a patient population with increased interdialytic weight gain
and noncompliance (p = 0.012) (Saxena et al., 2015). Study findings also included that patient
BP during treatments was >120/80 mmHg and that no IDH symptoms occurred, as patients were
overhydrated and did not achieve target weight (Saxena et al., 2015).
A systematic review and meta-analysis by Nesrallah et al. (2013) revealed that patients
who received the BVM treatments had lower IDH rates, along with a reduction of IDHassociated symptoms. Out of the eight studies included in the meta-analysis, six of the studies
changed the sodium concentration of the dialysate and the UF rate to maximize plasma refilling
(Nesrallah et al., 2013). Sodium biofeedback can theoretically cause positive sodium balance in
HD patients, however, the decreased rate of IDH in the study was not associated with increased
pre-dialysis BP, target weight (estimated patient weight, the goal weight trying to obtain after
HD treatment), interdialytic weight gain, or post-dialysis sodium serum levels (Nesrallah et al.,
2013). The data did not suggest that lower rate of IDH with the use of sodium modeling resulted
in positive sodium loading (Nesrallah et al., 2013).
In Nesrallah et al’s (2008) randomized control study, the authors primarily studied BVM
and its effects in extracellular fluid volume (ECFV). The authors reported that the frequency of
IDH was decreased with the use of BVM compared to SHD treatments (p = 0.04). Since the
BVM device also influences dialysate conductivity, it could potentially affect the patient’s serum
sodium base balance. However, serum sodium level changes were negligible and were not
statistically significant (p > 0.05) (Nesrallah et al., 2008).
Sentveld et al. (2008) conducted a prospective crossover study to determine whether
BVM was beneficial in improving hemodynamic stability and quality of life in HD patients as
compared to SHD. The study findings demonstrated that the use of BVM resulted in a
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significantly decreased pre-dialysis SBP (p = 0.003). Increased post-dialysis SBP was noted in
both groups, the SHD phase to the BVM phase (p = 0.018), and in the BVM phase to SHD phase
(p = 0.043) (Sentveld et al., 2008). Treatment time remained unchanged; thus, the duration of
treatment was not responsible for increased hemodynamic stability (Sentveld et al., 2008).
Quality of life in relation to post-dialysis fatigue was not significantly different between the
control and the intervention group (p > 0.05); however, there was a significant difference in
fatigue when switching from the BVM to the SHD phase (p = 0.035) (Sentveld et al., 2008).
Franssen at al. (2005) utilized a prospective clinical trial to study whether BVM
improved post-dialysis BP levels in IDH-prone patients and whether BVM is effective in
decreasing post-dialysis weight. IDH requiring intervention dropped from 64% (SHD phase) to
37% (BVM phase with constant target weight), and 28% (BVM phase with target weight
reduction) (p < 0.01). Post-dialysis SBP with BVM (constant weight and with target weight
reduction) was higher compared to those with SHD, but it was not statistically significant (p =
0.07), p = 0.15 respectfully) (Franssen et al., 2005). Alternatively, post-dialysis diastolic BP with
BVM was significantly higher compared to SHD (p < 0.05) (Franssen et al., 2005). Monitoring
BP post dialysis revealed an increase in SBP during the first 16 hours after the end of treatment
in the BVM group as compared to the control group (p < 0.05) (Franssen et al., 2005). These
findings can be attributed to: 1) BVM prevented extreme fluctuations of RBV and led to
improved hemodynamic stability and 2) stress caused by IDH required a recovery time (Franssen
et al., 2005). During the recovery time, the autonomic nervous system is less responsive to low
blood pressure by increasing heart rate and/or vasoconstriction and thus inhibits BP variation
(Franssen et al., 2005).

20

Du Cheyron et al. (2010) studied BVM in an acute kidney injury (AKI) patient
population in the intensive care unit (ICU) in a prospective randomized control trial. The authors
found that the implementation of BVM with blood temperature controls are feasible and safe (Du
Cheyron et al., 2010). The rate of hypotension decreased from 29% to 17% with the use of BVM
and blood temperature controls (p = 0.03) (Du Cheyron et al., 2010).
Some studies demonstrated no significant differences in IDH and IMEs. Four of the 17
studies found no correlation between BVM and decreased rates of IDH and IMEs.
In a prospective clinical crossover trial, Sentveld et al. (2008) that the frequency of
complaints associated with hypotension was reduced in both the BVM and the SHD group, but
the frequency did not reach statistical significance (p > 0.05). The participants had a SHD,
followed by BVM phase, and then another SHD phase. For the BVM group, the incidence of
complaints was 8.8% while the SHD groups in phase one and three were 14.6% and 12.8%
(respectively), but the results were not statistically significant (p > 0.05) (Sentveld et al., 2008).
Leung et al. (2017) conducted a randomized single-blind crossover trial assessing
whether BVM alone or BVM with adjustments to the dialysate resulted in a decrease in the
frequency of symptomatic IDH compared to SHD (control group). Leung et al. (2017) noted that
when the intervention treatment period data were combined, the rate of IDH did not differ
between the BVM intervention group and the control group (p = 0.29). The rate of IDH was
lower in the control period than in the run-in period (the period of the trial in which the dialysis
prescription was standardized, and target weights were adjusted), showing a 50.8% decline (p =
0.01). There were no significant differences in the degree of change in the frequency of IDH
from the run-in period to the control or the run-in period to the BVM period (p = 0.55) (Leung et
al., 2017). The number of treatments with symptomatic IDH (p = 0.52), asymptomatic IDH (p =
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0.67), and IMEs (p = 0.96) were consistent in relation to the primary analysis (Leung et al.,
2017). The rate of asymptomatic IDH, symptomatic IDH or IMEs was not decreased with the use
of BVM (Leung et al., 2017).
Du Cheyron et al. (2013) conducted a prospective three-arm randomized controlled trial
and compared the risks and benefits between BVM alone, BVM with BTM biofeedback, and
SHD with cool dialysate and high sodium conductivity. Du Cheyron et al. (2013) determined that
there was no difference in the rate of IDH between the BVM intervention group and the control
group in an AKI ICU patient population (p = 0.99) (Du Cheyron et al., 2013). SHD was also
compared with BVM and blood temperature monitoring and there was no decrease in the rate of
IDH (p = 0.39) (Du Cheyron et al., 2013).
Booth et al (2011) conducted a prospective audit of BVM records of 72 stable outpatient
adults to determine the usefulness of BVM. No relationship between BP and BVM could be
determined (Booth et al., 2011). A drop in SBP of ≥20mm Hg did not show a correlation with
the use of BVM or with the amount of fluid removed (Booth et al., 2011).
Adequacy & Target Weight
Adequacy in dialysis is measured by Kt/V values. These values can be determined by two
methods. One method is inserting the average blood volume processed during a dialysis
treatment into the interface of the dialysis machine, the value is determined by an algorithm in
the dialysis machine system and this is an estimated Kt/V value or single pool Kt/V (Advanced
Renal Education Program, 2015). This algorithm suggests that urea is confined to one
compartment in the body (Advanced Renal Education Program, 2015). The second, more precise
measurement of adequacy, called double pool or equilibrated Kt/V, is drawing a serum sample
(Advanced Renal Education Program, 2015). The result of the serum sample is plugged into the
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algorithm to determine the adequacy for the month (Advanced Renal Education Program, 2015).
Both are utilized in clinical practice, however, the double pool Kt/V is used to determine HD
prescription change.
Target weight is the goal weight to be achieved at the end of HD treatment. It helps
determine the amount of fluid to be removed and it is the anticipated post weight of the patient. It
has been suggested that BVM can increase adequacy and better determine precise target weights
(KDOQI, 2005).
Out of the 17 studies, 10 addressed target weight and/or adequacy (target weight [2],
adequacy [4], both target weight and adequacy [4]). Two of the six studies found no relation to
and/or not significant differences between target weight and BVM (Franssen et al., 2005; Gil et
al., 2014; McIntyre et al., 2003; Nesrallah et al., 2008). Four out of the eight studies found no
significant correlation between adequacy and BVM (Franssen et al., 2005; Gil et al., 2014;
Nesrallah et al., 2008; Santoro et al., 2002).
McIntyre et al. (2003) conducted a prospective study and demonstrated that although the
use of BVM did not affect target weight, there was a significant decrease in interdialytic weight
gain in unstable patients (p = 0.009). The researchers hypothesized that the decreased
interdialytic weight gain was due to a reduced thirst which occurred immediately after treatment.
McIntyre et al. (2003) also reported a significant increase in urea clearance with BVM as
compared to SHD (single pool p = 0.03, equilibrated p < 0.01).
In a randomized control study, Nesrallah et al. (2008) determined that extracellular fluid
volume and target weight were not reduced during the six month timeframe of the study. There
was no relationship between BVM and Kt/V (Nesrallah et al., 2008).
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Santoro et al. (2002) conducted a prospective randomized crossover trial and determined
that the Kt/V delivered during treatment was not significantly different, the control group and the
BVM group (p > 0.05). Weight loss between both groups was not significantly different (p >
0.05) (Santoro et al., 2002). The high responders (those benefiting the most from BVM) achieved
a weight 0.5 kg higher than those in SHD at the same weight loss (Santoro et al., 2002). The poor
responders (those not benefitting from BVM) had a lower post-dialysis weight with BVM than
with SHD (0.2 kg), but this corresponded with a higher total weight loss than SHD period (2.9 kg
[SHD] vs. 3.3 kg [BVM]) (Santoro et al., 2002)
In critical AKI patients, the incidence of hypotension was inversely related to adequacy
(Du Cheyron et al., 2010). Findings from this prospective randomized control study reported a
decrease in IDH, with the delivered Kt/V of 1.36 (± 0.39), exceeding the goal of 1.2 (Du
Cheyron et al., 2010).
In a different prospective three-arm randomized control trial by Du Cheyron et al. (2013),
the observed median Kt/V of 1.2 exceeded the prescribed goal.
In a pilot study by Saxena et al. (2015), the researchers reported that the BVM group was
better able to tolerate UF during treatments than the SHD group (3L of fluid removal in the
BVM group versus 1.9L in the SHD group).
Winkler et al. (2008) used a descriptive clinical study to evaluate a possible reduction in
lower target weights after BVM sessions in combination with lower dosage antihypertensive
drug therapy. BVM use decreased fluid overload of pure water caused by diabetes and
intermittent hyperglycemia (Winkler et al., 2008). Other benefits of BVM included higher Kt/V
results (p < 0.05, single pool; p < 0.05, double pool) as compared to SHD.
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In a crossover study, Sentveld et al. (2008) concluded that larger UF rates could be
achieved with BVM as compared to SHD (p = 0.049). The researchers also demonstrated a
significant decrease in target weight with the use of BVM as compared to SHD (p = 0.032)
(Sentveld et al., 2008).
Gil et al. (2014) completed a prospective crossover study which demonstrated that the
body weight (pre-dialysis weight [p = 0.456], post-dialysis [p = 0.432]) and intradialytic weight
gain (p = 0.320) did not differ from the BVM group and the control group (SHD group). Dialysis
adequacy measured by urea did not differ between the BVM group and the SHD control group (p
= 0.910) (Gil et al., 2014).
Franssen et al. (2005) completed a prospective study and noted that the Kt/V and target
weight reductions did not differ between the control (SHD) and the BVM group. Failure to
reduce target weight with BVM necessitated modification of target weight by changing the
dialysis prescription (e.g., increasing treatment time) (Franssen et al., 2005).
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DISCUSSION
Synthesis of current literature demonstrated the effectiveness of BVM in decreasing the
incidence of IDH (Basile et al., 2001; DuCheyron et al., 2010; Franssen et al., 2005; Gabrielli et
al., 2009; Gil et al., 2014; McIntyre et al., 2003; Nesrallah et al., 2013; Nesrallah et al., 2008;
Santoro et al., 2002; Saxena et al., 2015; Sentveld et al., 2008; Steuer et al., 1996; Veljančic et
al., 2011). BVM alleviated intradialytic symptoms of IDH such as muscle cramps, nausea,
dizziness, headache vomiting, unconsciousness, or other adverse symptoms requiring nursing
intervention (Basile et al., 2001; Gabrielli et al., 2009; McIntyre et al., 2003; Santoro et al., 2002;
Saxena et al., 2015; Steuer et al., 1996; Veljančic et al., 2011; Winkler et al., 2008). The benefits
of BVM use were seen in both patients prone to IDH and in non-IDH prone patients (Basile et
al., 2001; DuCheyron et al., 2010; Franssen et al., 2005; Gabrielli et al., 2009; Gil et al., 2014;
McIntyre et al., 2003; Nesrallah et al., 2013; Nesrallah et al., 2008; Santoro et al., 2002; Saxena
et al., 2015; Sentveld et al., 2008; Steuer et al., 1996; Veljančic et al., 2011). Patients in a more
critical condition, such as unstable cardiovascular patients, experienced greater benefit from the
use of BVM (Santoro et al., 2002).
BVM allows greater blood volume stability, which fosters less extreme conditions in
refilling and pressure rates (Santoro et al., 2002). Improved refilling rates increased ejection
fraction and nearly normalized LV mass index (Winkler et al., 2008). Patients who experienced
IDH and IDH-related symptoms did so at specific hematocrit thresholds (Steurer et al., 1996).
This threshold was consistent with successive treatments (Steurer et al., 1996).
The studies using sodium modeling in conjunction with BVM did not lead to positive
sodium loading after dialysis treatments (Basile et al., 2001; Nesrallah et al., 2013; Nessrallah et
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al., 2008). Blood pressure, body weight, and serum sodium levels remained the same in the
subsequent two years (Basile et al., 2001; Nesrallah et al., 2013; Nessrallah et al., 2008).
The literature synthesis showed no consensus on the improvement in the dialysis
adequacy and optimal target weight. Several studies measured Kt/V by a single pool and
equilibrated pool, however not all studies measured both or differentiated the values between the
two.
Although BVM technology was determined to be effective and allows for a safer dialysis
treatment, nursing judgment continues to be essential to provide high-quality and safe care to
patients. This includes advocating for an increase or decrease in hematocrit thresholds, so the
patient continues to reap benefits with the utilization of BVM during routine HD treatments.
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LIMITATIONS
Although the majority of the research studies analyzed in the literature review were
randomized controlled trials, studies higher in the hierarchy of evidence, there are limitations to
the literature review findings. One limitation is that not all the included studies used BVM as the
only independent variable. Some studies included BTM or sodium biofeedback with BVM (Du
Cheyron et al., 2013; Du Cheyron et al., 2010; Nesrallah, 2013; Nesrallah et al., 2008; Saxena et
al., 2015; Steurer et al., 1996; Veljančic et al., 2011; Winkler et al., 2008;). It was unclear
whether the benefits of reduced IDH and IMEs were attributed solely to the BVM.
Another limitation was that each study defined IDH differently. Some studies used the
KDOQI guidelines (Basile et al., 2001; Booth et al., 2011; Leung et al., 2017; Saxena et al.,
2015), and others described a hypotensive episode as one that required nursing intervention or
one that resulted in IMEs (DuCheyron et al., 2013; Gabrielli et al., 2009; Veljančic et al., 2011).
Other definitions included a drop in BP of ≥20 mmHg with symptoms (Frannsen et al., 2005; Gil
et al., 2014; Sentveld et al., 2008) or without symptoms (McIntyre et al., 2003). Other studies
created their own definition of hypotension such as DuCheyron et al. (2010), who described IDH
as SBP < 90 mm Hg or a drop in SBP of > 40 mm Hg from baseline that required intervention.
Santoro et al. (2002) defined IDH as: 1. a reduction of SBP to < 90 mm Hg with application of
nursing interventions, or 2. a combination of pre-dialysis SBP of ≥100 mm Hg with a decrease in
SBP ≤ 90 mmHg without symptoms, predialysis SBP of <100 mm Hg with symptoms or a
reduction in SBP of ≥25 mm Hg with symptoms. Nesrallah et al. (2008) defined IDH more
conservatively as a reduction in SBP of >10 mm Hg, requiring nursing intervention. Steuer et al.
(1996) used IMEs as end points into his study and included IMEs as an event, regardless of a
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drop in BP. Winkler et al. (2008) did not define IDH but did include IMEs, such as muscle
cramping.
Another limitation is the lack of studies within the last five years that address BVM
technology and its effects on IDH. Five studies are research published within the last 5 years,
indicating a gap in current literature. Additional research is warranted to determine the efficacy
of BVM to prevent IDH and other clinically relevant benefits of BVM.
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CONCLUSION
The literature review demonstrated that BVM is effective in preventing IDH and IME
events. Results did not reveal a strong correlation between BVM and decreased target weights or
increased dialysis adequacy (Kt/V). A clear global definition of IDH is needed based on the
widely disparate definitions used in the studies. Further research is merited that can examine the
effects of BVM use alone without the addition of other variables. The lack of recent studies in
the literature indicates that more research is merited in the use of BVM technology with dialysis
patients to support the use of BVM in clinical settings and to determine the population that will
benefit the most from this intervention. The barriers which prevent the implementation of BVM
in clinical settings warrants consideration.
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TABLE 1: HIERARCHY OF EVIDENCE
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TABLE 2: SUMMARY TABLE OF RESEARCH LITERATURE ON BLOOD VOLUME MONITORING

Study
Name

Authors

Randomize
d crossover
trial of
blood
volume
monitoringguided
ultrafiltratio
n
biofeedback
to reduce
intradialytic
hypotensive
episodes
with
hemodialysi
s.

Leung
K.C.W.,
Quinn
R.R.,
Ravani P.,
Duff H.,
and
MacRae
J.M.
(2017)

Design

Randomiz
ed single
blind
Crossover
Trial

Sample Size, Participants,
and Settings

Aim

n= 32
Mean age 67, women in
sample 17%, years in
dialysis 3.65, BMI 30, race:
White 17%, Asian 10%,
Other 6%; cause of ESRD:
DM, HTN, GN, obstructive
and other. Access: AVF
12% and CVC 20%.
Inclusion criteria: Age >18,
medically stable, on HD for
>3 months, treating 3-4
x/week for at least 3 hours
and ≥30% HD treatments
complicated by
symptomatic IDH in the
preceding 8 weeks.
Exclusion criteria: serum
hemoglobin <8.0 g/dl,
serum sodium <133 meq/L
active malignancy, history
of blood transfusion or
hospitalization in the
preceding 4 weeks, ongoing
urine output estimated
≥250mL/day, routinely
used diuretics for volume
management, a planned
change in the renal
replacement modality

Evaluate
whether
BVM alone
without
adjustment of
dialysate
resulted in
decrease in
symptomatic
IDH when
compared to
best clinical
practice.
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Key
Findings

Suggested
Interventio
ns

BVM did
not reduce
the rates of
symptomati
c IDH,
asymptomat
ic IDH or
symptoms
alone (p=
0.29).

More
studies to
determine
the specific
population
and the
optimal
critical
blood
volume to
best utilize
this
technology.

Strengths
(S) &
Limitations
(L)
S:
manipulative
variable is
BVM,
washout
period,
target weight
assessed
weekly,
defined IDH
and
predisposed
IDH sample.
L: Small
sample size,
strict
inclusions
and
exclusion
criteria
(<10% of
those
screened
were in the
study), and
not every BP
reading was
analyzed.

Relevance

Manipulati
ve variable
is BVM.

Level
of
Eviden
ce
Level I

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim

Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)

BVM with
BTM
strongly
correlated
with a
reduced rate
of IDH, the

BVM with
BTM
should be
included in
the dialysis
protocol.

S: IDH
defined
according to
KDOQI
guidelines
and no
consumption

Relevance

Level
of
Eviden
ce

during the study period, or
unable to provide written
informed consent.
Setting: Five outpatient HD
centers in Calgary, Alberta,
Canada.

Noninvasive
method for
preventing
intradialytic
hypotension

Saxena A.,
Sharma
R.K.,
Gupta A.,
and John
M.M.
(2015)

Longitudi
nal Pilot
Study

n= 40
Mean age 41.5 yrs, height
(cm) 165.5, BMI 21.1,
Hemoglobin (Hbg) (mg%)
8.44, Hematocrit (hct) (%)
27.8, platelets 196,000,
serum albumin (g/dL) 3.4,

Evaluate the
feasibility of
BVM and
blood
temperature
monitoring
(BTM)
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Interventio
n included
BVM.

Level
IV

Study
Name

Authors

Design

: a pilot
study.

Efficacy of
hemocontro
l
biofeedback
system in
intradialytic
hypotension
-prone
hemodialysi
s patients.

Gil H.W.,
Bang K.,
Lee S.Y.,
Han B.G.,
Kim J.K.,
Kim Y.O.,
Song H.C.,
Kwon Y.J.,
and Kim
Y.S.
(2014)

Multicenter
prospectiv
e
crossover
study

Sample Size, Participants,
and Settings

Aim

and serum creatinine mg
(%) 8.2
Inclusion criteria: ≥ 18years of age, non-diabetic,
dose of erythropoietin
constant for ≥3 months.
Exclusion criteria: overt
CHF, cardiac arrhythmia,
severe carotid stenosis,
history of symptomatic
cerebral vascular disease,
and positive viral markers
(HBV and HIV).
Setting: Dialysis unit in
tertiary care hospital
(India).

preventing
IDH prone
patients due
to
noncomplian
ce to fluid
restrictions
and to assess
changes in
water
compartment
s.

use of
nursing
intervention
s, and intraand interdialytic
symptoms
(p=0.012).

n= 60
Age 57, Male 31.6%,
Diabetes 31.6%, HTN
63.3%, mean time in
dialysis 58.3, vascular
access: AVF 76.7% and
AVG 23.3%, hgb (g/dL)
10.6, serum albumin (g/dL)
3.84, and Antihypertensive
meds ACE or ARBs 50%,
CCB 43.3%, α or β blocker
41.7%, Direct vasodilator
3.3%.
Inclusion criteria: chronic
HD patients on 3x/week
HD, >3 months on HD,

Determine
whether
hemocontrol
biofeedback
system
(HBS)
improves
IDH in IDH
prone
patients
compared
with
conventional
HD.

HBS
reduces
occurrence
of IDH (p
<0.001),
promote
faster
recovery
from post
dialysis
fatigue
(p =0.048),
and
decreases
IDH related
nursing
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Key
Findings

Suggested
Interventio
ns

HBS in
clinical
setting to
reduce IDH.

Strengths
(S) &
Limitations
(L)
of food or
fluids
allowed to
prevent
foodinduced
IDH.
L: Unclear
which
intervention
influenced
results, no
female in
sample, and
patients
received HD
2X/week.
S: First
multicenter
prospective
study that
assessed
HBS in
Asian patient
population,
large sample
size, defined
IDH similar
to KDOQI
guidelines,
and used
multiple
centers.

Relevance

HBS is a
form of
BVM.

Level
of
Eviden
ce

Level II

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim

>25% incidence of IDH
during the last month
preceding the study, age 1874, ability to provide
consent, and interdialytic
weight gain >1.5 kg.
Exclusion criteria: predialysis MAP in supine
position < 90 mmHg,
delivered blood flow rate
for dialysis < 200 mL/min,
pre-dialysis hemoglobin
level > 13 g/dL, treatment
by hemodiafiltration,
unstable angina, myocardial
infarction, decompensated
congestive heart failure,
history of hemodynamically
important valvular heart
disease, and expected need
for blood transfusions.
Setting: 9 outpatient HD
centers (Korea).

Key
Findings

intervention
s (p
<0.001).
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Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)
L: Results of
the study
cannot be
generalized
to other
populations,
cardiovascul
ar disease
was
determined
by history,
crossover
design bias
on subjective
assessment,
and target
weight
assessed by
study
physician
based on
clinical
evaluation.

Relevance

Level
of
Eviden
ce

Study
Name

Authors

Biofeedbac
k dialysis
for
hypotension
and
hypervolem
ia: a
systematic
review and
metaanalysis.

Nesrallah
G.E., Suri
R.S.,
Guyatt G.,
Mustafa
R.A.,
Walter
S.D.,
Lindsay
R.M., and
Akl E.A.
(2013)

Design

Systematic
Review &
metanalysi
s

Sample Size, Participants,
and Settings

Aim

Inclusion criteria: age >18,
3x/week dialysis for at least
90 days, chronic fluid
overload and symptomatic
IDH.
Exclusion criteria: Varied
by study included reduced
life expectancy, severe
anemia, pregnancy, and
cardiac arrhythmia.
Setting: ICHD.

To determine
whether
biofeedback
HD using
biofeedback
UF and/or
variation in
dialysate
conductivity
improves
outcomes in
patients with
chronic fluid
overload or
symptomatic
IDH
compared
with constant
UF and
conductivity.
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Key
Findings

Suggested
Interventio
ns

Biofeedbac
k dialysis
statistically
and
clinically
significant
reduced
frequency
of IDH.
No
evidence of
harmful
effects such
as sodium
loading
with
variation of
dialysate
conductivit
y.

Biofeedbac
k
technology
should be
considered
for IDH
prone
patients and
those with
expanded
ECF
volume.

Strengths
(S) &
Limitations
(L)
S: Imposed
no language
restriction on
language of
publication,
used detailed
search
strategy,
limited
metanalysis
to patient
important
outcomes.
L: Studies
were single
blinded,
unclear of
randomizatio
n techniques,
studies
included
biofeedback
that adjusted
dialysate
conductivity
unclear
which
intervention
was
effective.

Relevance

BVM
biofeedbac
k was the
interventio
n
implement
ed to guide
UF and
conductivit
y dialysate.

Level
of
Eviden
ce
Level I

Study
Name

Authors

Use of
online
blood
volume and
blood
temperature
monitoring
during
haemodialy
sis in
critically ill
patients
with acute
kidney
injury: a
singlecentre
randomized
controlled
trial.

du
Cheyron
D., Terzi
N., Seguin
A., Valette
X., Prevost
F.,
Ramakers
M.,
Daubin C.,
Charbonne
au P., and
Parienti
J.J. (2013)

Design

Prospectiv
e single
center
three arm
randomize
d
controlled
trial

Sample Size, Participants,
and Settings

Aim

n= 74
Average Age 65, , male
gender 68%, BMI 26.7,
comorbidities: HTN 47%,
CAD 27%, DM 100%;
Cause of AKI: septic shock
43%, cardiogenic 26%,
hypovolemia 11%, drug
induced 8%, and other
12%; BUN 18.2 mmol/L,
serum creatinine 245
μmol/L, number of sessions
4.5, number of days on
RRT in ICU days 9, length
of ICU stay 15 days, and
mortality 42%.
Inclusion criteria: AKI, ≥18
years with the first line of
RRT as intermittent
hemodialysis.
Exclusion criteria: ESRD,
patient requiring renal
replacement therapy that
was first initiated with
continuous veno-venous
hemofiltration, and AKI
dialysis session performed
with an a priori intentions
for no UF.
Setting: Medical ICU
admission (France).

Compare the
risks and
benefits of
HD protocols
either with
BV
biofeedback
or both BV
and BT
biofeedback
compared to
standard
dialysis
therapy with
cool dialysate
and high
sodium
conductivity.
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Key
Findings

Suggested
Interventio
ns

No
significant
difference
in
occurrence
of IDH with
BVM and
BVM with
BTM
compared
to standard
dialysis
treatment (p
= 0.99).

Further
research is
warranted
before
BVM
technology
is routinely
used in ICU
setting.

Strengths
(S) &
Limitations
(L)
S: Included
all AKI
related
dialysis
session with
UF and
study design.
L: Small
sample size,
critically ill
patients are
more prone
to IDH
versus stable
ESRD
patient,
decreased
population
variety, lack
of blinding
to medical
team, and
inability to
determine
critical BV.

Relevance

BVM was
tested
alone as an
interventio
n and
compared
to BVM
with BTM

Level
of
Eviden
ce
Level I

Study
Name

Authors

Do changes
in relative
blood
volume
monitoring
correlate to
hemodialysi
s-associated
hypotension
?

Booth J.,
Pinney J.,
and
Davenport
A. (2011)

Design

Prospectiv
e Audit

Sample Size, Participants,
and Settings

Aim

n=72
36.1% diabetic patients
with 20.8% with prescribed
insulin, mean age 55 years,
males and females
(50%/50%).
Exclusion criteria: Patients
with implanted
defibrillators and
resynchronization
pacemakers, patients unable
to stand on the
bioimpedance machine.
Setting: University dialysis
center (UK).

Assess the
usefulness in
relative BVM
audited
changes in
relative blood
volume in
heathy CKD
HD
outpatients to
determine
whether there
was a
correlation
with IDH.
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Key
Findings

Suggested
Interventio
ns

Unable to
determine
any
relationship
between
changes in
BVM and
intradialytic
blood
pressures.

BVM
techniques
solely based
on
hematocrit
could
potentially
underestima
te the effect
of UF on
plasma
volume.

Strengths
(S) &
Limitations
(L)
S: Patients
refrained
from eating
during HD
but could
drink 180mL
of fluid.
Large
sample size.
L:
Population
study did not
include IDH
prone
patients,
audit study
design, no
inclusion
criteria, and
did not
define IDH.

Relevance

BVM was
the
manipulati
ve
variable.

Level
of
Eviden
ce
Level
III

Study
Name

Authors

Simultaneo
us blood
temperature
control and
blood
volume
control
reduces
intradialytic
symptoms.

Veljančic
L.,
Popović J.,
Radović
M.,
Ahrenholz
P.,
Ries W.,
Frenken
L., and
Wojke R.
(2011)

Design

Randomiz
ed
crossover
clinical
trial

Sample Size, Participants,
and Settings

Aim

n= 26
Mean age 56.1 years, mean
time in dialysis 6.3 years,
12 males and 14 females,
comorbidities (n): HTN
(12), CAD (6), LVH (6),
and DM (2).
Inclusion criteria: Three
European countries study
population, ≥18 years,
thrice weekly HD
treatments lasting at least 3
hours, and a history of
cardiac instability during
HD. Exclusion criteria:
Severe instabilities with
blood pressure medications,
severe anemia, vascular
access problems, single
needle treatment, HD with
varying dialysate sodium
concentration or varying
ultrafiltration rates.
Setting: 6 European dialysis
centers.

To
investigate
the clinical
benefit of
simultaneous
control of
BTM and
BVM.
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Key
Findings

Suggested
Interventio
ns

Combined
use of
BVM and
BTM
provided an
average of
45% fewer
intradialytic
complicatio
ns
compared
to standard
HD
(p =
0.024).

In a
population
with high
incidence of
IME
combined
application
of both
individualiz
ed
automatic
biofeedback
systems is
suggested
as a
preventative
measure.

Strengths
(S) &
Limitations
(L)
S: Sample
prone to
IMEs,
screening
phase in
which
individual
patient
critical BV
was
determined,
and defined
IME.
L: Inability
to
distinguish
the
intervention
that caused
the
significant
improvemen
ts in IMEs,
the
intervention
was not
blinded by
no blinding,
and small
sample size.

Relevance

BVM was
used as an
interventio
n
alongside
BTM.

Level
of
Eviden
ce
Level I

Study
Name

Authors

Blood
volumeand blood
temperature
-controlled
hemodialysi
s in
critically ill
patients: a
6-month,
casematched,
open-label
study.

du
Cheyron
D.,
Lucidarme
O., Terzi
T., and
Charbonne
au P.
(2010)

Design

Prospectiv
e open
label, case
matched
study

Sample Size, Participants,
and Settings

Aim

n=20
Historical Control: n=42.
Age 61, male 43%,
comorbidities: hypertension
38% and cardiomyopathy
10%. Origin medicine 86%.
Cases: Age 59, male 60%,
Comorbidities:
hypertension 60% and
cardiomyopathy 30%.
Origin medicine 85%.
Age 61, male 43%,
Inclusion criteria: AKI in
oliguric stage dialyzed
exclusively by intermittent
hemodialysis (IHD).
Exclusion criteria: Patients
with end-stage renal disease
and dialysis treatments
involving administration of
packed red blood cells.
Setting: Medical ICU
(France).

Test the
feasibility
and safety of
concurrent
BV and BT
monitoring
during HD.
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Key
Findings

Suggested
Interventio
ns

Blood
volume
monitoring
and blood
temperature
monitoring
proved to
decrease
incidence of
hypotension
and
maintain
hemodyna
mic
stability (p
= 0.03).

Simultaneo
us BV and
BT
monitoring
are safe and
feasible in
AKI patient
in the ICU.

Strengths
(S) &
Limitations
(L)
S: Defined
safe,
feasibility,
and
hypotension.
Each pair of
patients and
dialysis
treatment
had to fulfill
4 conditions:
case patients
should have
the same age
( ±5 years)
and the same
SAPS II
(±10 points)
at ICU
admission as
historical
controls; and
among these
pairs of
patients,
online
monitoring
dialysis
sessions
should have
the same
dialysate
sodium

Relevance

Manipulati
ve variable
is BVM
technology
.

Level
of
Eviden
ce
Level II

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim

42

Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)
concentratio
n ( ±1
mmol/l) and
the same net,
ultrafiltratio
n per session
( ±500mL)
as
conventional
dialysis
sessions, and
no
statistically
significant
differences
between the
groups.
L: AKI
oliguric
patients were
the focus of
the study.
The
treatment
modality
included
temperature
and blood
volume
monitoring,
it remains
unknown
which

Relevance

Level
of
Eviden
ce

Study
Name

Authors

Improved
intradialytic
stability
during
haemodialy
sis with
blood
volumecontrolled

Gabrielli
D., Krystal
B.,
Katzarski
K.,
Youssef
M.,
Hachache
T., Lopot
F., Lasseur

Design

Open
randomize
d
crossover
study

Sample Size, Participants,
and Settings

Aim

n=26
Age 69.7, mean time on
RRT 4.5 years, % of males
53.8, 60, sessions with IME
47.5, Comorbidities no.:
DM 15.4%, coronary heart
disease 38.5%, myocardial
insufficiency 15.4%,
previous MI 15.4%, HF
34.6%, peripheral

Investigate
differences in
hemodynami
c stability
when
compared to
standard HD
with BVM
controlled
UF.
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Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)
variable
caused
increased
hemodynami
c stability.
ICU patients
were the
main
population
understudy.
Small
sample size.
Control
group used
was a
historical
control
group from
2007 treated
with
standard
IHD.

Relative
BVM
biofeedback
control of
UF
decreased
the
frequency
of IMEs (p
= 0.02) in

Use of
BVM
without
alteration in
sodium
dialysate to
decrease
IMEs.

S:
manipulative
variable
BVM, IME
prone
patients
selected,
eliminated
variables
that could

Relevance

Only
modified
variable
was BVM
guided UF.

Level
of
Eviden
ce

Level I

Study
Name

Authors

ultrafiltratio
n

C., Gunne
T.,
Draganov
B., Wojke
R., and
Gauly A.
(2009)

Design

Sample Size, Participants,
and Settings

Aim

arteriopathy 34.9%,
previous stroke 15.4%,
HTN 69.2%, autonomous
neuropathy 11.5%, cardiac
arrhythmia requiring
treatment 26.9%, and other
30.8%; 77% were on BP
meds and 85% were on
EPO.
Inclusion criteria: 3x/week
HD with at least 180
minutes of treatment time,
prone to IDH, 1/3 of
treatment was complicated
by intradialytic morbid
events (IME which are
hypotension, cramps,
nausea, vomiting, headache,
dizziness, or other adverse
symptoms requiring
medical intervention).
Exclusion criteria:
application of blood
temperature control, sodium
or UF profiles, planned
change in dialysate
composition or dose of
recombinant human
erythropoietin, current
intake of antihypotensive
medications, frequent
change in target weight, and

Key
Findings

hypotension
prone
patients
from 40%
(during
standard
HD) to
32%.
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Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)
affect blood
volume
control and
intradialytic
stability
were
eliminated
and dialysis
and
medication
prescription
were kept
constant.
L: patient
and user
bias, small
sample size,
and BVM
group had on
average 2
minutes
more than
prescribed
treatment
time.

Relevance

Level
of
Eviden
ce

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim

Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)

HBS did
not change
ECFV,
however
did
decrease
frequency
of IDH (p =
0.04)
compared
to best
clinical
practices.

It is
possible to
use HBS
software to
normalize
hydration
status by
increasing
ionic mass
removal to
gently
desalt
patients.
Further
studies are
needed.

S: Defined
IDH, large
sample size,
study length,
and baseline
period.
L: between
group
differences
at baseline,
selection
criteria not
based on
frequent
IDH or IME.
Also, HBS
used
biofeedback
changed
dialysate and
the UF rate
according to
RBV.

Relevance

Level
of
Eviden
ce

other severe medical
conditions.
Setting: Nine HD centers.
Can
extracellula
r fluid
volume
expansion
in
hemodialysi
s patients be
safely
reduced
using the
hemocontro
l
biofeedback
algorithm?
A
randomized
trial

Nesrallah
G.E., Suri
R.S.,
ThiessenPhilbrook
H.,
Heidenhei
m P., and
Lindsay
R.M.
(2008)

Open label
randomize
d control
study

n = 60
Best Clinical Practices
(BCP) (31): Age 68, male
67%, race: white 87%,
black 3%, native Canadian
10%; urine output
>200mL/d 26%,
Comorbidities: DM 24
77%, HTN 84%,
cardiovascular disease 77%;
Medications: Diuretics
16%, ACEI 55%, Beta
blocker 61%, and other
35%.
Hemocontrol Biofeedback
System (HBS) (29): Age
64.1, male 55%, race: white
86%, black 0%, native
Canadian 14%; urine output
>200mL/d 34%,
Comorbidities: DM 76%,
HTN 90%, cardiovascular
disease 76%; Medications:
Diuretics 28%, ACEI 48%,
Beta blocker 59%, and
other 45%.

Examine the
effects of
HBS when
compared to
best clinical
practices on
ECFV and
secondary
outcomes in
ECF
expanded HD
patients.

Inclusion criteria: HD thrice
weekly for at least 6 months
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HBS is
BVM
technology
, however,
the
biofeedbac
k system
changed
dialysate
conductivit
y.

Level I

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim

at the London Health
Science Center, predialysis
ECFV > 45% of total body
water, age 18-85, blood
flow rate ≥350mL/min,
treatment time ≥3.5 hours,
and hemoglobin 110-120
g/L.
Exclusion criteria: urine
output >400mL/day,
treatment with
hemofiltration/hemodiafiltr
ation, blood transfusion
dependence, pregnancy,
hemodynamic instability
due to arrhythmia, and use
of alpha-adrenergic agents
to prevent IDH
Setting: London Health
Science Center.

46

Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)

Relevance

Level
of
Eviden
ce

Study
Name

Authors

The
influence of
blood
volumecontrolled
ultrafiltratio
n on
hemodynam
ic stability
and quality
of life.

Sentveld
B., Van
den Brink
M., Brulez
H.F.H.,
Potter Van
Loon B.J.,
Weijmer
M.C., and
Siegert
C.E.H.
(2008)

Design

Prospectiv
e Multiple
crossover
study

Sample Size, Participants,
and Settings

Aim

n = 18 (19 enrolled 1
moved)
13 males and 6 females,
mean age 64, mean time on
HD 44 months, cause of
RF: diabetic neuropathy
(6), hypertensive
nephrosclerosis (5),
polycystic kidney disease
(3), chronic interstitial
nephritis (1), IgA
nephropathy (1), Wegener’s
granulomatosis (1), reflux
nephropathy (1), and
postrenal obstruction
nephropathy (1).
Inclusion criteria: Patients
treated 3 times weekly with
4-hr sessions
Exclusion Criteria: Patients
who received treatment for
cardiac failure or received
BV guided UF.
Setting: General Dialysis
department (Netherlands).

Determine
whether BV
controlled
UF compared
to
conventional
UF is
beneficial to
hemodynami
c stability
and quality of
life.
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Key
Findings

Suggested
Interventio
ns

BVM
demonstrate
improved
hemodyna
mic
stability
(pretreatment p
= 0.003,
posttreatment p
= 0.018),
increased
ultrafiltratio
n capacity
(p = 0.049),
and a
decrease in
dry weight
(p = 0.032).
But it does
not
demonstrate
a change in
quality of
life.

Use of
BVM in
clinical
setting to
increase
hemodynam
ic stability
and UF
capacity in
heterogeneo
us
population
of HD
patients.

Strengths
(S) &
Limitations
(L)
S:
determined
critical BV
before
initiating
intervention,
treatment
time
remained
unchanged,
objective
tool was
used to
determine
quality of
life, and IDH
was defined.
L: Small
sample size,
population
did not
equally
represent
females,
sample
population
did not
include IDH
prone
patients

Relevance

Interventio
n utilized
was BVM
biofeedbac
k HD.

Level
of
Eviden
ce
Level II

Study
Name

Authors

Blood
volume
monitoring.

Winkler
R.E.,
Pätow W.,
and
Ahrenholz
P. (2008)

Design

Descriptiv
e clinical
evaluation

Sample Size, Participants,
and Settings

Aim

n=18
11 males and 7 females
mean age 56.4
Inclusion criteria: Diabetic
patients with known
cardiovascular disease and
experienced HD related
complications like cramps
and IDH; age ≥18, and start
of RRT 39 months
Exclusion criteria: none
found.
Setting: not described.

BVM with
regulations of
UF and
sodium was
evaluated to
describe
advantages
for efficacy
and
compatibility
with HD.
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Key
Findings

Suggested
Interventio
ns

BVM
improved
the
adequacy (p
single pool
<0.05, p
double pool
<0.05)
compared
to SHD and
removal of
pure fluid
(p >0.05).
Also,
patient can
reach
optimal
weight (p
>0.05) with
reduced HD
related
complicatio
ns
(p <0.01)

BVM offers
a unique
possibility
to treat
diabetic
patients
according
to their
special
needs.

Strengths
(S) &
Limitations
(L)
S: Inclusion
of IDH
prone
patients.
L: Small
sample size,
BVM guided
UF with
sodium
intervention
- remains
unknown
which
intervention
proved to be
effective, no
sample
description,
and IDH not
defined.

Relevance

Manipulati
ve variable
in study
was BVM
guided UF,
however it
also
included
biofeedbac
k of
sodium.

Level
of
Eviden
ce
Level II

Study
Name

Authors

Automatic
feedback
control of
relative
blood
volume
changes
during
hemodialysi
s improves
blood
pressure
stability
during and
after
dialysis.

Franssen,
C.F.M.,
Dasselaar
J.J.,
Sytsma P.,
Burgerhof
J.G.M, de
Jong P.E.,
and
Huisman
R.M.
(2005)

Design

Prospectiv
e study

Sample Size, Participants,
and Settings

Aim

n=12
Age 64.2 years, mean time
on HD 4.5 years, causes of
CKD: DM (5), HTN (4),
PKD (1), lupus (1), and
acute RF after AAA rupture
(1), AVF and AVG (11
total) and CVC (1), major
cardiac comorbidity (2), BP
meds (6) and prescription
unchanged throughout
study, residual renal
function (3), hgb 7.4
mmol/L and albumin 37.7
g/L.
Inclusion criteria: chronic
HD for >6 months, HD 3
times/week, and
symptomatic IDH requiring
intervention in 50% of
sessions over the past 6
weeks.
Exclusion criteria: IDH
caused by primary cardiac
rhythm disturbances and a
history of frequent
transfusions of packed red
blood cells (defined as >2
units/month during the past
3 months).
Setting: ICHD
(Netherlands).

Whether
blood volume
tracking
(BVT)
improved
post dialysis
BP in
hypotensive
prone
patients and
whether BVT
is effective in
reducing post
treatment
weight.
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Key
Findings

Suggested
Interventio
ns

BVT is
associated
with better
intradialytic
hemodyna
mic
stability (p
<0.01) and
higher
systolic BP
after HD
(BVM with
constant
weight vs
SHD p
=0.07,
BVM with
reduction in
weight vs
SHD p =
0.15)
compared
to standard
HD.
However, it
is not able
to lower
post HD
weight (p
>0.05).

BVT is
effective in
reducing
IDH and
increase
systolic BP
up to 16
hours post
HD.

Strengths
(S) &
Limitations
(L)
S: Defined
IDH
treatment
interventions
, defined
IDH (not
defined as
KDOQI
guidelines),
and drew
pre- and
post- sodium
level labs.
L: Small
sample size,
adjusts both
dialysate
conductivity
(adjusts
sodium) and
BVT guided
UF.

Relevance

Manipulati
ve variable
was BVT a
form of
BVM
technology
.

Level
of
Eviden
ce
Level
III

Study
Name

Authors

Biofeedbac
k controlled
hemodialysi
s (BF-HD)
reduces
symptoms
and
increases
both
hemodynam
ic
tolerability
and dialysis
adequacy in
nonhypotension
prone stable
patients.

McIntyre
C.W.,
Lambie
S.H., and
Fluck R.J.
(2003)

Design

Prospectiv
e study

Sample Size, Participants,
and Settings

Aim

n=15
Mean age 66, 14 males and
one female.
Inclusion criteria: on HD
for >6 months at the
beginning of BF-HD,
dialyzing through an
established arteriovenous
fistula, considered stable
based on previous history,
prior to transfer to minimal
care facility. Patients HD
treatments complicated by
systolic BP >40% (IDH)
was 0.9 (0-3)
episodes/patient/3- week
period and significant
symptoms related to IDH
was 1 (0-4)
episodes/patient/3-week
period, and no patient had
interdialytic weight gains
>4kg.
Exclusion criteria: None
mentioned.
Setting: 4 station minimal
care dialysis facility within
in the author’s main unit
(UK).

Evaluate the
use of BFHD in
patients that
are
considered
stable
(representativ
e of most
chronic HD
patients).
Investigate
BVM and its
effect on
tolerability,
blood
pressure,
interdialytic
weight gain,
and urea
clearance.
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Key
Findings

Suggested
Interventio
ns

BF-HD can
improve
hemodyna
mic
tolerability
(p <0.001)
and
morbidity
(p <0.001).
In addition,
decrease
interdialytic
weight gain
(p = 0.009)
and
improve
urea
clearance
(single pool
p = 0.03,
equilibrated
p <0.01). .
Also,
decreases
the amount
of nursing
intervention
s for IDH.

BF-HD
may
possess
benefits for
a larger
dialysis
population
group than
existing
data
suggest.

Strengths
(S) &
Limitations
(L)
S:
prescription
optimization
period,
defined IDH,
no alteration
in blood
flow rate,
dialyzer type
or size, or
treatment
times; and
no alteration
in dietary
sodium
intake.
L: Small
sample size,
definition of
IDH was not
in
accordance
with KDOQI
guidelines,
changed UF
and dialysate
conductivity,
more males
than females
in sample,
and nonpone IDH
population.

Relevance

Manipulati
ve variable
is BF-HD
is BVM
technology
.

Level
of
Eviden
ce
Level II

Study
Name

Authors

Blood
volumecontrolled
hemodialysi
s in
hypotension
-prone
patients: a
randomized
,
multicenter
controlled
trial

Santoro
A.,
Mancini
E., Basile
C.,
Amoroso
L.., Di
Giulio S.,
Usberti
M.,
Colasanti
G.,
Verzetti
G., Rocco
A.,
Imbasciati,
Panzetta
G.,
Bolzani R.,
Grandi F.,
and
Polacchini
M. (2002)

Design

Multicente
r,
prospectiv
e,
randomize
d,
crossover
study

Sample Size, Participants,
and Settings

Aim

n=36
Mean age 67.1, mean time
on dialysis 41.8 months,
sex M/F 14/18, hgb 10.3
g/dL, hct 31.6, serum
albumin 3.9 g/dL, cause of
ESRD: glomerulonephritis
18.8%, interstitial
nephropathy 15.6%,
nephroangiosclerosis 25%,
PKD 18.8%, Diabetes
18.8%.
Inclusion criteria: HD 3
times/week, treatment time
≥180 minutes, stable
clinical conditions with
residual diuresis
≤400mL/day, stable hgb or
hct, a mean interdialytic
weight gain ≥1.5kg,
reduced hemodynamic
stability during HD (one
episode of acute IDH in 2080% of dialysis) in the last
two months prior to the
start of the study, and have
one of the following
comorbid conditions:
cardiac disease, DM I/II,
and arterial hypertension
(already present and
diagnosed for at least 6
months).

Compare
blood volume
tracking
system to
standard
bicarb
dialysis in
respect to
improvement
in tolerability
in a large
number of
IDH prone
patients.
Secondly,
identify
patient
parameters to
help
recognize
which
patients draw
the most
benefits from
continuous
and
automatic
BVM.
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Key
Findings

Suggested
Interventio
ns

BVM
improved
intradialytic
cardiac
stability (p
= 0.004)
with
improveme
nts in
interdialytic
symptoms
(p <0.001).
Population
that seemed
to respond
better to
this
treatment
were patient
with an
increased
risk for
IDH during
standard
HD and
nonhypotensive
pre-dialysis
BP.

This is the
first step in
a
physiologic
al dialysis
where
treatment
parameters
are
dynamically
changed by
the delivery
system
incorporatin
g adaptive
and logic
controls.

Strengths
(S) &
Limitations
(L)
S: Defined
IDH,
population
predisposed
to IDH,
multicenter
study, pre
and post
sodium level
draws once a
week.
L: Small
sample size
compared to
statistical
sample
analysis, 32
subjects
included in
statistical
analysis,
Kt/V is
estimated,
BV guided
conductivity,
and IDH was
not defined
within the
parameters
of KDOQI
guidelines.

Relevance

Manipulati
ve variable
is BVM
technology
.

Level
of
Eviden
ce
Level I

Study
Name

Efficacy
and safety
of
haemodialy
sis
treatment
with the
Hemocontr
ol
biofeedback
system: a
prospective
mediumterm study

Authors

Basile C.,
Giordano
R.,
Vernaglion
e L..,
Montanaro
A., De
Maio P.,
De Padova
F.,
Marangi
A.L., Di
Marco L..,
Santese D.,
Semeraro
A., and
Ligorio
V.A.
(2001)

Design

Multicente
r,
prospectiv
e,
randomize
d cross
over study

Sample Size, Participants,
and Settings

Exclusion criteria: The
presence of a persistent
intradialytic cardiac
instability (IDH occurred in
>80% of treatments).
Setting: 10 HD centers
(Italy).
n= 35
7 males and 12 females,
mean age 64.5, mean time
on dialysis 80.5 months,
and affected by different
nephropathies including
two with DM.
Inclusion criteria:
Maintenance standard
bicarb treatment for at least
6 months and hemodynamic
instability (≥20% HD
sessions complicated by
symptomatic IDH).
Exclusion criteria: None
described.
Setting: 10 Italian dialysis
units.

Aim

Assess
whether
bicarbonate
treatment
equipped
with HBS
was able to
decrease
cardiovascula
r instability
and patient
morbidity
compared
with standard
bicarbonate
treatment.
Compare the
efficacy and
safety of
HBS with
that of
standard
bicarbonate
treatment in
the medium
term.
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Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)

HBS is
effective in
reducing
IDH and
other intraand inter
dialytic
symptoms
(p <0.02).

HBS is an
effective
treatment in
decreasing
hypovolemi
a related
morbidity
than
standard
treatment.
Also, it is a
safe
treatment
for medium
term
because the
results are
attained
without
potential
harmful
changes in
BP, weight,
and serum
sodium
levels.

S: Defined
IDH,
patients
wrote down
symptoms
pre, intra and
post HD
(symptoms
were rated
on a 0-10
scale), blood
draws in the
beginning of
each month
(ABGs,
serum urea
nitrogen,
creatinine,
calcium,
sodium,
potassium,
phosphate,
uric acid,
hemoglobin,
and
hematocrit),

Relevance

HBS is the
manipulati
ve variable
(this is a
form of
BVM
technology
).

Level
of
Eviden
ce

Level I

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim
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Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)
nursing staff
recorded
IDH and
muscle
cramps, BP
was taken in
supine
position, no
eating or
drinking was
permitted
during
treatment,
L: Kt/V was
estimated
not
confirmed
by blood
draw, two
studies the
medium
study lacked
a time
control
group while
the shortterm study
included an
on/off
treatment
schedule, it
did not
identify

Relevance

Level
of
Eviden
ce

Study
Name

Authors

Design

Sample Size, Participants,
and Settings

Aim
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Key
Findings

Suggested
Interventio
ns

Strengths
(S) &
Limitations
(L)
asymptomati
c IDH, and
HBS also
changed
dialysate
conductivity.

Relevance

Level
of
Eviden
ce

Reducing
symptoms
during
hemodialysis
by
continuously
monitoring
the
hematocrit.

Steuer
R.R.,
Leypoldt
J.K.,
Cheung
A.K.,
Senekjian
H.O., and
Conis
J.M.
(1996)

Single
sample nonrandomized
control trial

n=6
Sample no described.
Inclusion criteria:
Dialysis staff determined
based on experience
which patients were IDH
prone.
Exclusion criteria: None
described.
Setting: University of
Utah affiliated
Bonneville Dialysis
Unit.

Exploit
critical
hematocrit
threshold to
design
strategies to
may reduce
intradialytic
morbidity
without
changing
treatment
times or
target
volume
removal.
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There are
other
symptoms
correlated
with
hypovolemia
that are not
reflected by
BP. BVM
appears to be
more useful
than BP
monitoring
in predicting
and
preventing
hypovolemia
induced
morbidity (p
0.02).

Hematocrit
threshold is a
valid concept
that shows a
two-fold
reduction in
hypovolemic
symptoms
without
extending
treatment
time or
reducing
target fluid
removal.
Large scale
studies are
needed to
determine
what patient
population
would most
benefit from
this
technique.

S: Defined
IDH, no blood
transfusions
given, and
used
intradialytic
symptoms as
end points for
intradialytic
morbidity
without
changes in BP
improved
standard
deviations and
hematocrit
thresholds.
L: Small
sample size,
sodium
concentration
fluctuated
during
treatment,
lacked wash
out period, did
not included
asymptomatic
IDH, and did
not include
various other
symptoms that
occurred
during HD.
Sample not
described.

Crit-lines
are a form
of BVM
technology.

Level
III
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